Galectin Therapeutics announced today the company will participate in the 9th Edition of the Paris NASH meeting. This year, Galectin Therapeutics, in collaboration with HistoIndex of Singapore, will present a poster on the use of artificial intelligence to better explore the complex histology of liver cirrhosis resulting from NASH and highlight potential differences between lean cirrhotic patients and overweight/obese cirrhotic patients. Pol Boudes, MD, Chief Medical Officer of Galectin Therapeutics, commented: “Artificial Intelligence is an interesting tool that can improve the definition, description, and understanding of architectural changes in the liver tissue of cirrhotic patients. Current histology methods are not precise enough to be clinically relevant to stage the cirrhotic process and, consequently, are not generally used in clinical practice. Conventional histology is also not granular enough and not quantitative enough to evaluate the efficacy of candidate drugs. We are happy to contribute to the scientific progress in this field by sharing our data collected in our previous phase 2 cirrhosis program and by using the innovative technology that our colleagues at HistoIndex have developed.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GALT:
- Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
- Galectin Therapeutics reports Q2 EPS (15c) vs (16c) last year
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update